Hunter Immunology Overview
- Founded
-
2003
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Financing Rounds
-
1
Hunter Immunology General Information
Description
Developer of medicinal drugs intended to treat patient suffering from chronic obstructive pulmonary disease (COPD).
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Acquirer
Bioxyne
Primary Office
- Avalon Parade 61
- Sydney, New South Wales 2107
- Australia
Hunter Immunology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hunter Immunology Patents
Hunter Immunology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2013901154-A0 | Killed bacterial treatment of otitis media | Inactive | 04-Apr-2013 | ||
| AU-2012901052-A0 | Oral pharmaceutical and method of treatment of otitis media | Inactive | 16-Mar-2012 | ||
| AU-2009294321-B2 | Non-typeable haemophilus influenzae vaccines and their uses | Active | 17-Sep-2008 | 0000000000 | 0 |
| US-20110206765-A1 | Non-typeable haemophilus influenzae vaccines and their uses | Active | 17-Sep-2008 | 0000000000 | |
| EP-2334311-A2 | Non-typeable haemophilus influenzae vaccines and their uses | Active | 17-Sep-2008 | A61K39/102 |
Hunter Immunology Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| David Radford | Chief Executive Officer |